Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ascension Orthopedics' Titan

This article was originally published in The Gray Sheet

Executive Summary

Modular total shoulder system gains FDA market go-ahead, announced Sept. 2. The device is designed to provide multiple shoulder arthroplasty surgery solutions in a single implant system, the company explains. It offers a bone-preserving option for patients needing total or hemi-shoulder arthroplasty, allows surgeons to select distal stems and proximal bodies that best match patients' anatomy and bone quality, and includes 26 humeral head sizing options

You may also be interested in...



Integra Enters Shoulder Market, Builds Upper Extremity Biz Via Ascension Purchase

Integra LifeSciences will expand its orthopedic extremity implant offerings and bolster its upper extremity business in particular while entering the shoulder market for the first time with its $65 million acquisition of Ascension Orthopedics, announced Sept. 12.

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT029329

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel